Jiangxi Fushine Pharmaceutical Co., Ltd. (300497.SZ)
CNY 8.44
(-0.12%)
CNY 8.44
(-0.12%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -18.49 Million CNY | -78.75% |
| 2022 | 22.22 Million CNY | -38.58% |
| 2021 | 178.55 Million CNY | -62.13% |
| 2020 | 476.48 Million CNY | 2.07% |
| 2019 | 457.99 Million CNY | 49.1% |
| 2018 | 303.96 Million CNY | 20.83% |
| 2017 | 261.56 Million CNY | 3.97% |
| 2016 | 246.63 Million CNY | 58.16% |
| 2015 | 144.7 Million CNY | 63.44% |
| 2014 | 96.35 Million CNY | 22.29% |
| 2013 | 78.94 Million CNY | 20.12% |
| 2012 | 74.65 Million CNY | 58.96% |
| 2011 | 41.85 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | -31.79 Million CNY | -146.24% |
| 2024 Q1 | 15.07 Million CNY | 164.79% |
| 2024 Q2 | -12.91 Million CNY | -122.47% |
| 2023 Q3 | -7.42 Million CNY | 59.21% |
| 2023 FY | - CNY | -78.75% |
| 2023 Q1 | -21.39 Million CNY | 76.78% |
| 2023 Q4 | -88.7 Million CNY | -1094.33% |
| 2023 Q2 | -18.21 Million CNY | 14.88% |
| 2022 Q2 | 27.51 Million CNY | -30.76% |
| 2022 Q3 | 12.68 Million CNY | -53.88% |
| 2022 Q4 | -92.15 Million CNY | -826.27% |
| 2022 FY | - CNY | -38.58% |
| 2022 Q1 | 39.73 Million CNY | 135.52% |
| 2021 Q1 | 95.77 Million CNY | 202.63% |
| 2021 Q2 | 91.47 Million CNY | -4.49% |
| 2021 Q4 | -111.86 Million CNY | -1535.8% |
| 2021 FY | - CNY | -62.13% |
| 2021 Q3 | 7.79 Million CNY | -91.48% |
| 2020 Q3 | 92.33 Million CNY | -46.89% |
| 2020 Q1 | 108.17 Million CNY | -7.81% |
| 2020 Q4 | 31.64 Million CNY | -65.73% |
| 2020 FY | - CNY | 2.07% |
| 2020 Q2 | 173.86 Million CNY | 60.73% |
| 2019 Q1 | 72.4 Million CNY | 48.68% |
| 2019 Q4 | 117.33 Million CNY | -10.25% |
| 2019 FY | - CNY | 49.1% |
| 2019 Q3 | 130.73 Million CNY | 57.1% |
| 2019 Q2 | 83.21 Million CNY | 14.94% |
| 2018 Q3 | 53.04 Million CNY | -33.21% |
| 2018 FY | - CNY | 20.83% |
| 2018 Q4 | 48.69 Million CNY | -8.2% |
| 2018 Q2 | 79.42 Million CNY | -7.93% |
| 2018 Q1 | 86.26 Million CNY | 102.9% |
| 2017 Q3 | 52.47 Million CNY | -15.82% |
| 2017 Q2 | 62.33 Million CNY | 0.72% |
| 2017 Q4 | 42.51 Million CNY | -18.98% |
| 2017 FY | - CNY | 3.97% |
| 2017 Q1 | 61.89 Million CNY | -9.97% |
| 2016 FY | - CNY | 58.16% |
| 2016 Q1 | 45.12 Million CNY | -4.15% |
| 2016 Q3 | 49.01 Million CNY | -26.14% |
| 2016 Q4 | 68.75 Million CNY | 40.27% |
| 2016 Q2 | 66.35 Million CNY | 47.05% |
| 2015 Q2 | 37.88 Million CNY | 17.39% |
| 2015 Q4 | 47.08 Million CNY | 7.67% |
| 2015 Q3 | 43.72 Million CNY | 15.43% |
| 2015 Q1 | 32.26 Million CNY | 25.74% |
| 2015 FY | - CNY | 63.44% |
| 2014 FY | - CNY | 22.29% |
| 2014 Q1 | 22.34 Million CNY | 0.0% |
| 2014 Q4 | 25.66 Million CNY | 0.0% |
| 2013 FY | - CNY | 20.12% |
| 2012 FY | - CNY | 58.96% |
| 2011 FY | - CNY | 0.0% |